Short Interest in Cibus, Inc. (NASDAQ:CBUS) Decreases By 32.9%

Cibus, Inc. (NASDAQ:CBUS) was the target of a significant decline in short interest in December. As of December 15th, there was short interest totaling 816,246 shares, a decline of 32.9% from the November 30th total of 1,215,762 shares. Based on an average daily volume of 205,182 shares, the short-interest ratio is currently 4.0 days. Approximately 3.0% of the shares of the stock are sold short. Approximately 3.0% of the shares of the stock are sold short. Based on an average daily volume of 205,182 shares, the short-interest ratio is currently 4.0 days.

Cibus Stock Down 2.9%

Shares of CBUS stock opened at $1.70 on Monday. Cibus has a twelve month low of $1.09 and a twelve month high of $3.40. The stock’s fifty day simple moving average is $1.48 and its 200 day simple moving average is $1.47. The firm has a market capitalization of $92.28 million, a P/E ratio of -0.52 and a beta of 1.62.

Cibus (NASDAQ:CBUS) last announced its quarterly earnings results on Thursday, November 13th. The company reported ($0.44) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.03). Cibus had a negative net margin of 3,133.92% and a negative return on equity of 133.90%. The firm had revenue of $0.62 million for the quarter, compared to analyst estimates of $1.39 million. As a group, equities research analysts expect that Cibus will post -2.96 EPS for the current fiscal year.

Institutional Trading of Cibus

Several institutional investors have recently modified their holdings of the business. Rockland Trust Co. acquired a new stake in Cibus in the third quarter valued at $26,000. Qube Research & Technologies Ltd bought a new stake in shares of Cibus in the 2nd quarter valued at about $39,000. Warberg Asset Management LLC acquired a new stake in shares of Cibus in the second quarter valued at about $41,000. FNY Investment Advisers LLC bought a new position in shares of Cibus during the second quarter worth about $54,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Cibus in the third quarter worth approximately $62,000. Institutional investors own 33.81% of the company’s stock.

Analyst Upgrades and Downgrades

CBUS has been the topic of several recent analyst reports. Canaccord Genuity Group reiterated a “buy” rating and issued a $15.00 price target on shares of Cibus in a research note on Monday, December 8th. Weiss Ratings reissued a “sell (e+)” rating on shares of Cibus in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and a consensus price target of $20.00.

About Cibus

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.